Compare Expeditors International of Wshngtn Inc (EXPD) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Hims and Hers Health Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $181.24 (market cap $23.24B), while Hims and Hers Health Inc trades at $34.32 (market cap $8.60B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 2.7× Hims and Hers Health Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.91% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| EXPD | HIMS | |
|---|---|---|
Market Cap | $23.24B | $8.60B |
Sector | Industrials | Health |
52-Week High | $178.22 | $66.18 |
52-Week Low | $111.37 | $14.52 |
Enterprise Value | $22.49B | $8.98B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $180.87, up 1.49% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, posting Q1 2026 EPS of $1.71 versus $1.33 expected. Revenue grew to $11.07B in 2025 with a 7.48% net margin and impressive 36.59% ROE. Recent dividend of $0.81 reinforces shareholder returns while cash flow trends show operational strength.
Despite trading above the $161.50 consensus target, EXPD's earnings momentum and operational efficiency support continued upside potential. Key risks include analyst skepticism with only 12% buy ratings and overbought technical conditions. The stock's premium valuation requires sustained execution amid transportation industry challenges and economic uncertainties.
Hims & Hers Health trades at $34.78, down 1.05% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported $2.35B revenue in 2025 but faces profitability challenges with a negative net income margin of -0.56% and elevated valuation ratios including a P/E of 57.14. Recent news highlights expansion in weight-loss therapies and international markets, with Q2 2026 earnings due August 10, 2026.
The outlook remains cautiously optimistic with analyst consensus at Buy (35%) and a $33.57 price target near current levels. Key opportunities include GLP-1 therapy growth and subscriber additions, while risks involve profitability pressures, competitive threats, and reliance on regulatory approvals. The stock's performance hinges on execution in high-margin segments and cost management amid expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
